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To study the protective effect of prostacyclin (PGI2) we
increased PGI2 production by infected NRK-52E cells with
an adenovirus carrying cyclooxygenase-1 and prostacyclin
synthase. PGI2 overexpression protected these cells from
gentamicin-induced apoptosis by reducing cleaved caspase-3
and caspase-9, cytochrome c, and decreasing generation of
reactive oxygen species. Expression of the nuclear receptor of
PGI2, peroxisome proliferator-activated receptor-a (PPARa),
was reduced during gentamicin treatment of the cells, while
its overexpression significantly inhibited gentamicin-induced
apoptosis and the amount of cleaved caspase-3.
Transformation with PPARa short interfering RNA abolished
the protective effect of PGI2 overproduction in gentamicin-
treated cells. The PPARa activator docosahexaenoic acid
given to gentamicin-treated mice significantly reduced the
number of apoptotic cells in renal cortex, but this protective
effect was not seen in PPARa knockout mice. Our study
suggests that increased endogenous PGI2 production
protects renal tubular cells from gentamicin-induced
apoptosis through a PPARa-signaling pathway.
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Gentamicin is a widely used aminoglycoside antibiotic for the
treating Gram-negative bacterial infection, but its clinical use
is limited because gentamicin-induced acute renal failure
with acute tubular necrosis occurs in about 20% of patients.1
Although the intravenously administered gentamicin is
almost entirely eliminated by the kidney, a small but toxic
portion is selectively reabsorbed and accumulated in the
proximal tubular cells.1,2 Inducing apoptosis is an important
cytotoxic mechanism of gentamicin, which has been reported
in gentamicin-treated renal proximal tubular cells and
mesangial cells.3–5 Servais and co-workers4,6 reported that
the concentration of gentamicin in the 1- to 3-mM range is
related to the onset of gentamicin-induced apoptosis. The
mitochondrial pathway has been reported to involve in
gentamicin-induced apoptosis in LLC-PK1 cells,6 which
induces a major caspase activation to cause apoptosis in
mammalian cells.7 Additionally, reactive oxygen species
(ROS) are often responsible for the mitochondria-mediated
signaling pathway of apoptosis. A lot of in vivo and in vitro
evidence indicates that ROS are important mediators of
gentamicin-induced apoptosis.8 Therefore, the ROS-mediated
apoptosis signaling plays a major role in gentamicin-induced
cytotoxicity.
Prostacyclin (PGI2), one of the major prostaglandins
(PGs), is originated from arachidonic acid by the cyclooxy-
genase (COX) system coupled to the action of PGI2 synthase
(PGIS).9 PGI2 acts on platelets and blood vessels through its
specific cell-surface receptor (IP receptor), thereby inhibiting
platelet function and dilating blood vessels.10 Besides, recent
reports show that PGs are also the ligands of peroxisome
proliferator-activated receptors (PPARs), which belong to a
family of ligand-activated transcription factors.11 The
agonists of PGI2, cPGI and iloprost, can effectively induce
DNA binding and transcriptional activation by PPARa and
PPARd,12 but the same effect did not exist in those
experimental conditions with PGI2 treatment alone, possibly
because the chemical instability of this PG precluded it to
reach the nuclear target. PGI2 is also known to inhibit
leukocyte functions such as migration and ROS production13
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and inhibit mesangial cell proliferation.14 Another PGI2
analogue, beraprost, has been reported to prevent
radiocontrast nephropathy in LLC-PK1 cells.15 These data
reveal the protective effect of PGI2 on certain cell types.
Recently, we selectively augmented PGI2 production
through adenovirus-mediated transfer of genes for COX-1
and PGIS to rat renal tubular cells, and protected cells from
the apoptosis induced by adriamycin, an antitumor anthra-
cycline antibiotic.16 This implies the therapeutic potential of
endogenous PGI2 for nephrosis. Moreover, recent studies
have established that the use of fibrates, PPARa ligands,
ameliorates ischemia–reperfusion and cisplatin-mediated
proximal tubule cell death by prevention of lipotoxicity,
inhibition of fatty acid oxidation, and prevention of renal
inflammation.17–20 Therefore, we hypothesize that PPARa is
involved in the protective mechanism of PGI2 because this
PG is a potential activator for PPARa. In this study, we
intended to evaluate the protective effect of PGI2 on
gentamicin-induced injury in rat renal tubular cells with
the adenovirus-mediated bicistronic COX-1/PGIS transfec-
tion, and to investigate PPARa’s in vitro and in vivo
protective effects.
RESULTS
Ad-COX-1/PGIS transfection protects NRK-52E cells against
gentamicin-induced apoptotic injury
To determine the gentamicin-induced apoptosis in rat renal
tubular cell NRK-52E, we treated NRK-52E cells with
gentamicin and detected them with enzymatic labeling of
DNA strand breaks using terminal deoxynucleotidyl transfer-
ase-mediated deoxyuridine triphosphate nick end-labeling
(TUNEL). With different administration time, the apoptosis
cells were markedly increased by treatment with 3 mM of
gentamicin for 24 h, and ascended along the administration
time (Figure 1a). In the dosage test, 2 mM of gentamicin was a
minimal requirement to induce significant apoptosis in
NRK-52E cells within 24 h (Figure 1b).
The production of PGI2 was typically monitored by
measurement of 6-keto-prostaglandin F1a (6-keto-PGF1a)
because 6-keto-PGF1a is a stable product of the non-
enzymatic hydration of PGI2. Compared with the adenoviral-
human phosphoglycerate kinase (Ad-HPGK) control in
Figure 2a, Ad-COX-1/PGIS transfection increased PGI2 levels
in a dose-dependent manner. We also examined the
protective effect of Ad-COX-1/PGIS with TUNEL staining.
Figure 2b shows that Ad-COX-1/PGIS transfection reduced
gentamicin-induced apoptosis in a dose-dependent manner.
The result of the study also reveals that the endogenous PGI2
increase caused by Ad-COX-1/PGIS transfection protects rat
renal tubular cells from gentamicin-induced apoptosis.
Effect of Ad-COX-1/PGIS transfection on apoptosis signaling
induced by gentamicin in NRK-52E cells
To evaluate the mechanism of the protective effect of
Ad-COX-1/PGIS transfection on gentamicin-induced apoptosis,
the influence of Ad-COX-1/PGIS transfection on the cellular
uptake of gentamicin was first monitored. NRK-52E cells
were transfected with Ad-COX-1/PGIS or Ad-HPGK at 40
multiplicity of infection (MOI) for 2 days, and then treated
with 3 mM of gentamicin. As shown in Figure 3a, there was a
basal level of gentamicin in the 0-h groups. This may result
from gentamicin adhering to the cell membranes of NRK-
52E cells. After gentamicin treatment, the concentration of
cytosol gentamicin reached a maximum within 30 min.
Compared with Ad-HPGK transfection, Ad-COX-1/PGIS
transfection did not influence the concentration of cytosol
gentamicin. This result reveals that Ad-COX-1/PGIS trans-
fection did not influence the cellular uptake of gentamicin.
We next examined whether Ad-COX-1/PGIS transfection
prevents gentamicin-induced ROS formation because ROS
generation is involved in gentamicin-induced apoptosis.
Ad-COX-1/PGIS- or Ad-HPGK-transfected cells were treated
with 3 mM of gentamicin for 24 h. Gentamicin-induced
increases in intracellular ROS were revealed by fluorescent
intensities of 20,70-dichlorofluorescein (DCF). As shown
in Figure 3b, Ad-COX-1/PGIS transfection significantly
inhibited gentamicin-induced ROS formation. On the other
hand, Ad-COX-1/PGIS transfection significantly induced the
activity of antioxidant enzymes, superoxide dismutase (SOD)
and catalase, in NRK-52E cells (Figure 3c and d).
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Figure 1 | Gentamicin-induced apoptosis in NRK-52E cells.
(a) Time-dependent apoptosis induced by gentamicin as revealed by
TUNEL assays. NRK-52E cells were treated with 3 mM of gentamicin
from 12 to 48 h, harvested, stained with TUNEL assay, and examined
by fluorescence microscopy. The level of apoptosis was presented
as the percentage of TUNEL-positive cells for each treatment.
(b) Dose-dependent apoptosis induced by gentamicin as revealed by
TUNEL assays. NRK-52E cells were treated with gentamicin at 1–5 mM
for 24 h. Results are the mean±s.d. (n¼ 6). *Po0.05 compared with
the group without gentamicin treatment.
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Caspase-dependent signaling plays a major role in
apoptotic signaling pathway.21 We evaluate caspase-3 and
caspase-9 activities stimulated by gentamicin by monitoring
the quantity of cleaved subtypes of caspase-3 and caspase-9 in
NRK-52E cells. Figure 3e indicates that the cleaved subtypes
of both caspase-3 and caspase-9 were significantly elevated in
the cells treated with gentamicin. Compared with Ad-HPGK
transfection, Ad-COX-1/PGIS transfection significantly re-
duced the quantity of cleaved subtypes of both caspase-3 and
caspase-9 in gentamicin-treated NRK-52E cells. The increase
of cleaved caspase-9 is associated with mitochondria-
mediated signaling pathway in apoptosis.
We also monitored the influence of Ad-COX-1/PGIS
transfection on two mitochondria-associated signaling mo-
lecules, cytochrome c and Bcl-xL. Figure 3e shows that in the
gentamicin-alone treatment group, cytosol cytochrome c was
increased significantly and the expression of Bcl-xL was
reduced, but the variations of cytosol cytochrome c and
Bcl-xL were inhibited by Ad-COX-1/PGIS transfection.
Ad-COX-1/PGIS transfection induced the translocation of
PPARa
PPARa, a potential PGI2 receptor, has been reported
inhibiting cisplatin-mediated proximal tubule cell death.17
To evaluate the possibility that PPARa is involved in the
protective mechanism of PGI2, we monitored the mRNA
level of PPARa in NRK-52E cells using real-time polymerase
chain reaction. Figure 4a shows that gentamicin significantly
reduced the transcription level of PPARa compared with
non-treated control cells. Neither Ad-HPGK nor Ad-COX-1/
PGIS obviously influences the mRNA level of PPARa in
NRK-52E cells with or without gentamicin treatment.
The quantity of total PPARa protein in Ad-COX-1/PGIS-
transfected cells was also similar to that in Ad-HPGK-
transfected cells (data not shown). Figure 4b shows that the
nuclear PPARa protein in NRK-52E cells was significantly
increased by the 12-h transfection of Ad-COX-1/PGIS, and
ascended along the transfection time. This result reveals that
PGI2 generated by Ad-COX-1/PGIS transfection induces the
translocation of PPARa.
PPARa plays a crucial role in the protective mechanism of
PGI2 generated by Ad-COX-1/PGIS transfection in NRK-52E
cells
Inducing the translocation of PPARa implies that PPARa
plays a role in the protective mechanism of PGI2. We first
overexpressed PPARa fusion protein in NRK-52E cells to
evaluate the protective effect of PPARa against gentamicin-
induced apoptosis. Figure 5a shows that Flag-PPARa
construction overexpressed the fusion protein in NRK-52E
cells compared with controls or vector transformants. Figure
5b indicates that PPARa overexpression significantly reduced
the quantity of cleaved caspase-3 in gentamicin-treated NRK-
52E cells. In TUNEL assays, PPARa overexpression signifi-
cantly reduced gentamicin-induced apoptosis in NRK-52E
cells (Figure 5c). Figure 6a demonstrates that PPARa over-
expression inhibited the gentamicin-induced ROS, and Figure
6b and c show that the activity of catalase and SOD was also
increased in Flag-PPARa-transformed NRK-52E cells.
We applied gene knockdown to analyze the relationship
between PPARa and the protective effect of PGI2. Figure 7a
shows that NRK-52E cells were transfected with the PPARa
short interfering RNA (siRNA), and the PPARa transcription
level was obviously reduced. As shown in Figure 7b and c,
PPARa siRNA did not affect gentamicin-induced apoptosis
and cleaved caspase-3, but reduced the inhibition of Ad-
COX-1/PGIS transfection on the gentamicin-induced apop-
tosis and cleaved caspase-3.
The protective effect of PPARa on gentamicin-induced
apoptosis in vivo
The protective effect of PPARa on gentamicin-induced
apoptosis was further proven with docosahexaenoic acid in
vivo. Docosahexaenoic acid (DHA), a long-chain fatty acid, is
known as one of the PPARa activators.22 Normal and
PPARa-deficient mice were treated with gentamicin
(20 mg kg1 day1) or saline as controls; the experimental
groups were treated with DHA (200 mg kg1 day1) in
addition. At the end of the treatment period (7 days), the
renal function of experimental mice was monitored by
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Figure 2 | The influence of Ad-COX-1/PGIS transfection on NRK-
52E cells. (a) The levels of 6-keto-PGF1a in transfected NRK-52E cells.
NRK-52E cells were transfected with Ad-COX-1/PGIS (Ad-C/P) at
different MOI for 2 days. Ad-HPGK transfection was included as a
control. Results are the mean±s.d. (n¼ 6). *Po0.05 compared with
the expression level of 6-keto-PGF1a in Ad-HPGK transfected cells.
(b) The protective effect of Ad-COX-1/PGIS transfection against the
gentamicin-induced apoptotic injury in NRK-52E cells. NRK-52E cells
were transfected with Ad-COX-1/PGIS (Ad-C/P) or Ad-HPGK at
different MOI for 2 days, and then treated with 3 mM of gentamicin
for 24 h. The level of apoptosis was presented as the percentage of
TUNEL-positive cells for each treatment. Results are the mean±s.d.
(n¼ 6). *Po0.05 compared with the gentamicin alone group;
C represents untreated control.
580 Kidney International (2008) 73, 578–587
o r i g i n a l a r t i c l e Y-H Hsu et al.: PGI2 reduces gentamicin-induced apoptosis via PPARa
measuring the concentration of blood urea nitrogen and
serum creatinine. Figure 8a and c show that the concentra-
tions of blood urea nitrogen and serum creatinine were not
influenced by DHA treatment alone, but elevated in
gentamicin-treated groups, and that this gentamicin-induced
elevation was significantly inhibited by DHA treatment. The
influence of DHA treatment on gentamicin uptake in mouse
kidneys was also monitored at 120 min after the single
injection of gentamicin without or with DHA (Figure 8b).
There was no significant difference between the gentamicin
quantity in mouse kidneys with and without DHA treatment.
This result reveals that DHA did not influence the gentamicin
uptake in mouse kidneys. In addition, morphology study of
tubular injury in mouse kidneys was carried out with
hematoxylin and eosin staining. In normal mice, gentamicin
caused swollen and vacuolated epithelial cell degeneration
with tubular dilatation and intraluminal cell debris, which
was reduced by DHA treatment (Figure 8d). Compared with
normal mice, gentamicin caused more serious degeneration
and necrosis of epithelial cells, with granular and protei-
naceous casts in tubular lumen in PPARa-deficient mice
irrespective of DHA treatment (Figure 8d).
To analyze gentamicin-induced apoptosis, we next exam-
ined kidney sections after having detected DNA fragmenta-
tions with the in situ TUNEL assay. As shown in Figure 8e,
total nuclei in kidney sections were shown as bright spots
stained with 40,6-diamidino-2-phenyindole. The scattered
and bright nuclei stained by TUNEL staining could easily be
detected over the entire cortex from gentamicin-treated
animals, yet they were rarely detected in the specimens of the
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Figure 3 | Effects of Ad-COX-1/PGIS transfection on gentamicin-induced apoptotic signaling. (a) The concentrations of cytosol
gentamicin in NRK-52E cells. The NRK-52E cells were treated with 3 mM gentamicin for different time periods with Ad-COX-1/PGIS (solid bars) or
Ad-HPGK transfection (blank bars) at 40 MOI. The concentration of gentamicin in each sample was detected as described in Materials and
Methods. Data are expressed as the mean±s.d. (n¼ 6). (b) The inhibitory effect of Ad-COX-1/PGIS transfection on gentamicin-induced
ROS generation in NRK-52E cells. NRK-52E cells were transfected with Ad-COX-1/PGIS or Ad-HPGK at 40 MOI for 2 days, and then treated
with 3 mM of gentamicin for 24 h. Gentamicin-induced increases in intracellular ROS were revealed by fluorescent intensities of DCF.
Fluorescence intensities of cells are shown as the relative intensity of experimental groups compared with untreated control cells. Results
are the mean±s.d. (n¼ 6). *Po0.05 compared with the Ad-HPGK-transfected group with gentamicin treatment. (c, d) The influence of
Ad-COX-1/PGIS transfection on the activity of SOD and catalase in NRK-52E cells. The transfected cells were harvested and the activity
of SOD and catalase was analyzed using ELISA assay. Results are the mean±s.d. (n¼ 6). *Po0.05 compared with the Ad-HPGK-transfected
group with gentamicin treatment. (e) Effects of Ad-COX-1/PGIS transfection on caspases, cytochrome c, and Bcl-xL in gentamicin-treated
NRK-52E cells. Transfected cells were treated with 3 mM of gentamicin for 24 h. Western blotting was carried out with the specific
antibody against cleaved caspase-3 and caspase-9, cytochrome c, and Bcl-xL. Glyceraldehyde-3-phosphate dehydrogenase was used as a
loading control. C/P, Ad-COX-1/PGIS transfection; H, Ad-HPGK transfection; C, untreated control.
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controls and gentamicin–DHA-treated animals (Figure 8e).
Most of the TUNEL-labeled nuclei were seen in proximal
tubule epithelium. This result reveals that the PPARa
activator DHA inhibits the gentamicin-induced cell apoptosis
in the renal cortex in mice. Furthermore, the protective
effect of DHA on gentamicin-induced apoptosis was also
evaluated in PPARa-deficient mice. In PPARa-deficient mice,
TUNEL-labeled nuclei detected in the cortex from gentami-
cin-treated animals were much more than that in normal
mice (Figure 8f). Besides, the gentamicin-induced apoptosis
was rarely reduced by DHA treatment in PPARa-deficient
mice (Figure 8f).
DISCUSSION
The result in our previous study has shown that the
cotransfection of COX-1 and PGIS selectively augments
PGI2 synthesis in NRK-52E cells as well as protects cells from
adriamycin injury.16 The results of this study indicate that
Adv-COX-1/PGIS-induced PGI2 augmentation is also effec-
tive in reducing apoptotic death caused by gentamicin
(Figure 2). We monitored the apoptotic signals associated
with gentamicin, such as increase of cleaved caspase-3,
caspase-9, and cytochrome c release, and decrease in
Bcl-xL. These apoptotic signals present in gentamicin-treated
NRK-52E cells were reversed by Ad-COX-1/PGIS transfection
(Figure 3e). Besides, gentamicin-induced ROS generation was
also inhibited by Ad-COX-1/PGIS transfection (Figure 3b).
This inhibition should be associated with the elevation of the
activity of catalase and SOD caused by Ad-COX-1/PGIS
transfection (Figure 3c and d). Since ROS are an important
apoptotic stimulator, the inhibition of ROS generation is
supposed to be one of protective mechanisms of PGI2.
PPARa is supposed to be a potential nuclear receptor for
PGI2.
11,12 As shown in Figure 4a, the PPARa mRNA level was
found to be significantly inhibited in gentamicin-treated
NRK-52E cells, and not influenced by Ad-COX-1/PGIS
transfection, but the finding of our study showed that Ad-
COX-1/PGIS transfection activated PPARa, resulting PPARa
translocation (Figure 4b). Gentamicin-induced apoptosis was
significantly reduced after having overexpressed PPARa in
NRK-52E cells (Figure 5). Besides, gentamicin-induced
apoptosis was more serious in renal tubular cells in
PPARa-deficient mice compared with that in normal mice
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Figure 5 | Effects of PPARa overexpression on gentamicin-
induced apoptotic signaling. (a) The PPARa expression level in
NRK-52E cells with Flag-PPARa construct transformation. The level of
Flag-PPARa fusion protein in each sample was determined by
western blot analysis with anti-Flag and anti-PPARa antibodies.
(b) Protein levels of cleaved caspase-3 in transformed NRK-52E cells
treated with gentamicin. Transformed NRK-52E cells were treated
with 3 mM of gentamicin for 24 h, and then analyzed using western
blotting with the specific antibody against cleaved caspase-3.
(c) The protective effect of Flag-PPARa transformation against the
gentamicin-induced apoptosis in NRK-52E cells. Transformed
NRK-52E cells were treated with 3 mM of gentamicin for 24 h, and
then stained by TUNEL assay. Results are the mean±s.d. (n¼ 6).
*Po0.05 compared with the blank vector transformants with
gentamicin treatment. C, untransformed controls; V, blank vector
transformants; P, Flag-PPARa construct transformants.
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(Figure 8). Based on the finding of the study, we suggest that
PPARa is associated with the inhibition of gentamicin-
induced apoptosis in renal tubular cells. Since some PPAR-a
ligands, such as certain fatty acids, originally are present in
cytosol, the overexpression of PPARa in NRK-52E cells is
supposed to increase the active form of PPARa. As shown in
Figure 6, the PPARa ligand DHA can also protect renal
tubular cells from gentamicin-induced apoptosis in normal
mice. Therefore, the protective function of PPARa on
gentamicin-induced apoptosis should result from the activa-
tion of PPARa. Additionally, endogenous PGI2 augmentation
caused by Ad-COX-1/PGIS transfection lost the protective
effect in PPARa siRNA-transfected cells (Figure 7). DHA also
lost protective effect on gentamicin-induced apoptosis in renal
tubular cells in vivo (Figure 8). These results are direct evidences
to prove that the activation of PPARa is crucial for the
protective function of PGI2 on gentamicin-induced apoptosis in
renal tubular cells. But the detailed protective mechanism of
PPARa is not clear yet. Our results revealed that the activation
of PPARa did not influence gentamicin uptake in vitro and
in vivo (Figures 3a and 8b). Similar to Ad-COX-1/PGIS
transfection, overexpressing PPARa could activate catalase and
SOD, and inhibit gentamicin-induced ROS generation in
NRK-52E cells (Figure 6). We suggest that the PGI2 protective
effect on gentamicin-induced apoptosis is due to PPARa’s
inhibiting ROS generation in renal tubular cells.
Although PGI2 is supposed to be the ligand of PPARs, the
connection between endogenous PGI2 and the activation of
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effect of Flag-PPARa transformation on gentamicin-induced ROS generation. NRK-52E cells were transformed with the Flag-PPARa construct
and then treated with 3 mM of gentamicin for 24 h. Gentamicin-induced increases in intracellular ROS were revealed by fluorescent intensities of
DCF. Fluorescence intensities of cells are shown as the relative intensity of experimental groups compared with untreated control cells. Results
are the mean±s.d. (n¼ 6). *Po0.05 compared with the blank vector transformants with gentamicin treatment. (b, c) The influence of
Flag-PPARa transformation on the activity of SOD and catalase in NRK-52E cells. The transformed cells were harvested and the activity of SOD
and catalase was analyzed using ELISA assay. Results are the mean±s.d. (n¼ 6). *Po0.05 compared with the blank vector transformants group
with gentamicin treatment. C, untransformed controls; V, blank vector transformants; P, Flag-PPARa construct transformants.
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Figure 7 | Effects of the blocking of PPARa expression on the
protective effect of Ad-COX-1/PGIS transfection in NRK-52E cells.
(a) The PPARa mRNA level in NRK-52E cells with PPARa siRNA
transformation. Total RNA in each sample was extracted and applied
in real-time polymerase chain reaction assays. (b) The influence of
PPARa siRNA transformation on the protective effect of Ad-COX-1/
PGIS in NRK-52E cells. NRK-52E cells transformed with PPARa siRNA or
mock control siRNA were transfected with or without Ad-COX-1/PGIS
at 40 MOI for 2 days, treated with 3 mM of gentamicin for 24 h, and
then stained by TUNEL assays. Results are the mean±s.d. (n¼ 6).
(c) Protein levels of cleaved caspase-3 in siRNA-transformed NRK-52E
cells treated with gentamicin. Each sample was analyzed using
western blotting with the specific antibody against cleaved caspase-
3. C, untransformed controls; M, mock controls; sP, PPARa siRNA
transformants.
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Figure 8 | The protective effect of DHA against gentamicin-induced renal injury in vivo. Normal and PPARa-deficient mice were
injected with saline, gentamicin, or gentamicin and DHA. Concentrations of blood urea nitrogen and serum creatinine were measured
at the end of the treatment. (a) The concentration of blood urea nitrogen in treated mice. (c) The concentration of serum creatinine in treated
mice. Results are the mean±s.d. (n¼ 6). *Po0.05 compared with the gentamicin alone group. (b) Accumulation of gentamicin in mouse
kidney. The gentamicin quantity in the kidneys of normal and PPAR-a-deficient mice was measured at 120 min after the intraperitoneal
injection of gentamicin without or with DHA. Results are the mean±s.d. (n¼ 3).(d) Representative photomicrographs of hematoxylin and
eosin staining. Bar¼ 50mm (n¼ 5). (e) Apoptotic cells in the renal cortex of the gentamicin-treated mice. (f) Apoptotic cells in the renal
cortex of the PPARa-deficient mice with gentamicin treatment. TUNEL-labeled nuclei were revealed as bright spots in cortex sections from
untreated and treated mice. The identical fields stained for TUNEL were also stained using 40,6-diamidino-2-phenyindole to reveal the
positions of cell nuclei. Bar¼ 100 mm.
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PPARa is still not conclusive.11 The data in this study prove
that Adv-COX-1/PGIS transfection induces the activation of
PPARa in NRK-52E cells. Previous studies have shown that
Adv-COX-1/PGIS transfection is effective in augmenting
COX-1 and PGIS expression, and increases PGI2 without
overproduction of other prostanoids in endothelial, cerebral,
and rat renal tubular cells.16,23,24 We speculate that this
endogenous augmented PGI2 can interact with and activate
PPARa without the interference of other PGs. Through
PPARa-signaling pathway, PGI2 can negate gentamicin-
induced apoptosis; but several recent independent reports
show that endogenously produced PGI2 indeed activates
PPAR-d in vivo,25–27 and then uses PPARd to modulate
apoptotic process as well.11,28 Differing in results of our
study, these data in the literature indicate that PGI2 plays a
proapoptotic role. Besides different kinds of experimental
cells, the data about the proapoptotic effect of PGI2 are often
obtained with COX-2/PGIS cotransfection but not Ad-COX-
1/PGIS transfection applied in this study. The difference
between the physiological effects of COX-1 and COX-2 may
cause the PGI2 experimental diversity. Possibly, PGI2 has both
proapoptotic and antiapoptotic effects through activating
PPARd and PPARa, respectively. The mechanism of how
both opposite effects of PGI2 are regulated is still unknown.
In summary, Adv-COX-1/PGIS transfection can increase
the endogenous PGI2 production to inhibit gentamicin-
induced ROS generation, to enhance Bcl-xL expression, to
reduce cytochrome c release and the activity of caspases, and
eventually to protect NRK-52E cells from gentamicin-induced
apoptosis. The findings of our present study also show that
PGI2 could protect the injury due to PPARa activation. With
gentamicin treatment, the expression level of PPARa was
significantly reduced in NRK-52E cells, resulting in apoptotic
signals to negate PPARa’s protective effect. Overexpressing
PPARa or transfecting Ad-COX-1/PGIS to activate PPARa in
cultured cells can inhibit gentamicin-induced apoptosis
extensively. In mice, the PPARa ligand DHA also protected
renal tubular cells from gentamicin-induced apoptosis, but not
in PPARa-deficient animals. Based on these findings, we
suggest that the activation of PPARa can improve the
gentamicin-induced injury in kidney.
MATERIALS AND METHODS
Reagents
Dulbecco’s modified Eagle’s medium, fetal calf serum, and tissue
culture reagents from Invitrogen Corporation (Carlsbad, CA, USA).
All other chemicals of reagent grade were obtained from Sigma
(St Louis, MO, USA). Antibodies used in this research were
purchased from BD Biosciences (San Jose, CA, USA) and Santa Cruz
Biotechnology (Santa Cruz, CA, USA).
Cell culture
We purchased rat proximal renal tubular cells (NRK-52E) from
Bioresource Collection and Research Center (Hsinchu, Taiwan), and
cultured them in Dulbecco’s modified Eagle’s medium supplemented
with antibiotic/antifungal solution and 10% fetal calf serum. They were
grown until the monolayer became confluent. The medium for the
cultured cells was then changed to the serum-free medium and the cells
were incubated overnight before the experiment.
TUNEL staining
We detected gentamicin-mediated apoptosis in NRK-52E cells by
enzymatically labeling DNA strand breaks using TUNEL stain. As
described previously,16 TUNEL staining was performed with a Cell
Death Detection kit (Roche, Mannheim, Germany). To reveal total
nuclei, we stained the same slides with 40,6-diamidino-2-phenyindole
(1mg ml1) in phosphate-buffered saline plus 0.5% 1,4-diazabicyclo
[2,2,2]octane. Additionally, we also processed kidney slides with an
ApopTag Fluorescein in situ apoptosis detection kit (Chemicon
International Inc., Temecula, CA, USA) according to the manufac-
turer’s instructions. Briefly, kidney-tissue slides were incubated with the
reaction mixture containing terminal deoxynucleotidyl transferase
and digoxigenin-conjugated dUTP for 1 h at 371C, and mounted
with mounting solution containing 40,6-diamidino-2-phenyindole and
observed with fluorescent microscope.
Preparing replication-defective recombinant adenoviral
vectors
We constructed the replication-defective recombinant adenoviral
vector with two separate HPGK promoters (bicistronic) to drive
COX-1 and PGIS (Ad-COX-1/PGIS), and an HPGK alone to serve as
control (Ad-HPGK) as previously described.23 Replication-defective
recombinant adenoviral vectors were generated by homologous
recombination and amplified in 293 cells as described previously.23
Measuring PGI2 by enzyme immunoassay
Cells were sonicated in 1 ml of ice-cold buffer (0.05 M Tris at pH 7.0,
0.1 M NaCl, and 0.02 M EDTA) and centrifuged at 55 000 g for 1 h.
The supernatant was analyzed using 6-keto-PGF1 enzyme-linked
immunosorbent assay kits from R&D Systems Inc. (Minneapolis,
MN, USA) for PGI2 detection.
Determining cellular uptake of gentamicin
We cultured the NRK-52E cells in 6-cm plates with 3 mM gentamicin
for different time periods with Ad-COX-1/PGIS or Ad-HPGK
transfection at 40 MOI for 2 days, washed them three times with
phosphate-buffered saline buffer, and then lysed them with
immunoprecipitation assay buffer. The 0-h group cells were washed
immediately after gentamicin treatment. The concentration of
gentamicin in each sample was detected using Gentamicin EIA kits
according to instructions provided by the manufacturers (Euro-
Diagnostica BV, Arnhem, The Netherlands).
Detecting intracellular ROS
Before the chemical treatment, we incubated NRK-52E cells in
culture medium containing a fluorescent dye, DCF of 30 mM, for
30 min to establish a stable intracellular level of the probe.
Subsequently, the cells were washed with phosphate-buffered saline,
removed from Petri dishes by scraping, and measured for DCF
fluorescence intensity using fluorescence spectrophotometer with
excitation and emission wavelengths at 475 and 525 nm, respectively.
The cell number in each sample was counted and utilized to
normalize the fluorescence intensity of DCF. We also detected the
activity of catalase and SOD in NRK-52E cells by using Catalase
Assay kit and Superoxide Dismutase Assay kit according to
instructions provided by the manufacturers (Cayman Chemical
Company, Ann Arbor, MI, USA).
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Western blot analysis
A total of 30 mg of NRK-52E lysate proteins were applied to each
lane and analyzed by western blotting. The antibodies to PPARa,
Flag, caspase-3, caspase-9, cytochrome c, Bcl-xL, and glyceraldehyde-
3-phosphate dehydrogenase were diluted to 1:1000 for assay.
Peroxidase-conjugated anti-rabbit or anti-goat IgG was used as the
second antibody to detect primary antibodies by enhanced
chemiluminescence (Amersham Biosciences Corp., Piscataway, NJ,
USA). The preparation of nuclear protein extracts has been
described previously.16
RNA extraction and the real-time polymerase chain reaction
analysis
Total RNA was extracted from NRK52E cells using the TRIzol
method according to the protocol recommended by the manufac-
turer (Invitrogen Corporation).
PPARa mRNAs were quantified using SYBR Green Master Mix
(QIAGEN GmbH, Hilden, Germany) with specific primers in a
GeneAmp ABI prism 7000 (Applied Biosystems, Foster City,
CA, USA). The primers for PPARa were as follows: antisense
50-CCACCATCGCGACCAGAT-30, sense 50-GACGTGCTTCCTGCT
TCATAGA-30. Calibrated and non-template controls were included
in each assay. Each sample was run in triplicate. SYBR Green dye
intensity was analyzed using the ABI prism 7000 SDS software
(Applied Biosystems). All results were normalized to glyceraldehyde-
3-phosphate dehydrogenase. All quantifications were performed in
triplicate samples for three separate experiments.
Immunoprecipitation
NRK-52E cells were transfected with Ad-COX-1/PGIS or Ad-HPGK
at 40 MOI for different periods. The cells were lysed at 41C in lysis
buffer (50 mM Tris, pH 7.5, 1% Nonidet P-40, 0.5% sodium
deoxycholate, 150 mM NaCl, protease inhibitors). PPARa was
collected by using the immunoprecipitation kit (Roche Molecular
Biochemicals, Mannheim, Germany) with PPARa antibody (sc-
9000; Santa Cruz Biotechnology), following the manufacturer’s
instructions.
PPARa cDNA and siRNA transfection
The PPARa cDNA was kindly gifted by Dr SK Shyue (Institute of
Biomedical Sciences, Academia Sinica, Taipei, Taiwan), and the
PPARa siRNA (catalog number M-005714-00) was purchased from
Panomics Inc. (Fremont, CA, USA). Cells with or without Ad-COX-
1/PGIS transfection were grown to 70% confluence, and Flag-
PPARa construct or PPARa siRNA and their respective control
oligonucleotides were transfected using the Lipofectamine reagent
according to the manufacturer’s instructions (Invitrogen, Carlsbad,
CA, USA).
Animals and treatments
Male BALB/c mice weighting 20–25 g and aged 8 weeks were
obtained from Animal Center, Taiwan University, Taipei, Taiwan.
The PPARa-deficient mice were purchased from Charles River
Laboratories International Inc. (Wilmington, MA, USA). We housed
animals in a central facility submitted them to a 12-h light–dark
cycle, and provided them with regular rat chow and tap water.
The experimental group animals (n¼ 6) for gentamicin
treatment received to intraperitoneal injection with gentamicin
(20 mg kg1 day1) for 7 days. The animals (n¼ 6) for gentamicin
and DHA treatment received by intraperitoneal injection DHA
(200 mg kg1 day1) 30 min before the gentamicin treatment each
time. The control group rats received a continuous infusion of 0.9%
(w/v) saline throughout the gentamicin treatment period. Treated
and control mice were killed 24 h after the last drug injection and
blood samples were collected from the stump for the measurement
of serum creatinine and blood urea nitrogen. Both the kidneys were
harvested by laparotomy and the renal cortex tissue was snap–frozen
in dry ice and stored at 801C until in situ TUNEL assays. For
histological analysis, the harvested kidneys were fixed in 10%
formalin and embedded in paraffin, and sectioned at 4-mm
thickness, then stained with hematoxylin and eosin. In mouse
gentamicin uptake study, kidneys were excised at 120 min after the
single administration into mice. The tissues were weighed and
homogenized with phosphate-buffered saline buffer. The concentra-
tion of gentamicin in each sample was detected using Gentamicin
EIA kits according to instructions provided by the manufacturers
(Euro-Diagnostica BV).
Statistical analysis
Data were presented as the mean±standard deviation (s.d.), and
groups were compared using analysis of variance.
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